2012
DOI: 10.2223/jped.2167
|View full text |Cite
|
Sign up to set email alerts
|

A critical appraisal of the recommendations for the use of meningococcal conjugate vaccines

Abstract: Objectives:To assess the epidemiology of meningococcal disease (MD) in Brazil and the impact that recent evidence and lessons learned from the introduction of meningococcal C conjugate (MCC) vaccines into immunization programs may have on different strategies of vaccine use.Sources: Non-systematic review of the MEDLINE, SciELO and LILACS databases covering the period from 2000 to 2011. Summary of the findings:Meningococcal disease is endemic in Brazil, with periodic occurrence of outbreaks. Most cases are asso… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
9
0
4

Year Published

2014
2014
2020
2020

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 13 publications
(13 citation statements)
references
References 38 publications
0
9
0
4
Order By: Relevance
“…However, there are exceptions (Table S1) [24]. For instance, in 2010, Brazil introduced a MenC vaccine into their national immunization program in response to an increased incidence of IMD among infants and young children and recurring outbreaks throughout the country [25,26]. The vaccine was administered at age 3 and 5 months, with a booster dose given at age 12-15 months.…”
Section: Surveillance Disease and Vaccinationmentioning
confidence: 99%
“…However, there are exceptions (Table S1) [24]. For instance, in 2010, Brazil introduced a MenC vaccine into their national immunization program in response to an increased incidence of IMD among infants and young children and recurring outbreaks throughout the country [25,26]. The vaccine was administered at age 3 and 5 months, with a booster dose given at age 12-15 months.…”
Section: Surveillance Disease and Vaccinationmentioning
confidence: 99%
“…4 Em 2011, após a campanha de vacinação, foi evidenciada uma redução de 71% no número de casos da doença em relação à incidência de 2010. 8 Apesar de todos os esforços para atingir a cobertura vacinal, alguns locais ainda não alcançaram a meta estabelecida 9 e um dos fatores que tem-se mostrado associado é o nível socioeconômico individual 10 e da região. 11 Outros motivos, como falta de acesso e dificuldades na utilização de serviços, também podem estar relacionados à menor cobertura vacinal.…”
Section: Introductionunclassified
“…A capacidade da Nm permutar o material genético responsável pela produção da cápsula pode alterar o sorogrupo. Como a proteção conferida pelas vacinas é sorogrupo específica, esse fenômeno pode ter consequências na utilização e formulação das vacinas antimeningocócicas (SÁFADI et al, 2012;MUSTAPHA et al, 2016).…”
Section: Agente Etiológicounclassified